SEARCH

SEARCH BY CITATION

References

  • 1
    Eastham JA, Kattan MW, Riedel E et al. Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol 2003; 170 (6 Pt 1): 22922295
  • 2
    Fitzsimons NJ, Presti JC Jr, Kane CJ et al. Is biopsy Gleason score independently associated with biochemical progression following radical prostatectomy after adjusting for pathological Gleason score? J Urol 2006; 176 (6 Pt 1): 24532458
  • 3
    Hernandez DJ, Epstein JI, Trock BJ, Tsuzuki T, Carter HB, Walsh PC. Radical retropubic prostatectomy. How often do experienced surgeons have positive surgical margins when there is extraprostatic extension in the region of the neurovascular bundle? J Urol 2005; 173: 446449
  • 4
    Ploussard G, Agamy MA, Alenda O et al. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naive patients. BJU Int 2011; 107: 17481754
  • 5
    Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3478 consecutive patients: long-term results. J Urol 2004; 172: 910914
  • 6
    Van der Kwast TH, Bolla M, Van Poppel H et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 2007; 25: 41784186
  • 7
    Kordan Y, Salem S, Chang SS et al. Impact of positive apical surgical margins on likelihood of biochemical recurrence after radical prostatectomy. J Urol 2009; 182: 26952701
  • 8
    Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 15911597
  • 9
    Hong MK, Namdarian B, Corcoran NM et al. Prostate tumour volume is an independent predictor of early biochemical recurrence in a high risk radical prostatectomy subgroup. Pathology 2011; 43: 138142
  • 10
    Daskivich TJ, Regan MM, Oh WK. Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4. J Urol 2006; 176: 19271937
  • 11
    Corcoran NM, Hovens CM, Metcalfe C et al. Positive surgical margins are a risk factor for significant biochemical recurrence only in intermediate-risk disease. BJU Int 2012; 110: 821
  • 12
    Antonarakis ES, Chen Y, Elsamanoudi SI et al. Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database. BJU Int 2011; 108: 378385
  • 13
    Swindle P, Eastham JA, Ohori M et al. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 2005; 174: 903907
  • 14
    Cao D, Kibel AS, Gao F, Tao Y, Humphrey PA. The Gleason score of tumor at the margin in radical prostatectomy is predictive of biochemical recurrence. Am J Surg Pathol 2010; 34: 9941001
  • 15
    Cao D, Humphrey PA, Gao F, Tao Y, Kibel AS. Ability of linear length of positive margin in radical prostatectomy specimens to predict biochemical recurrence. Urology 2011; 77: 14091414
  • 16
    Brimo F, Partin AW, Epstein JI. Tumor grade at margins of resection in radical prostatectomy specimens is an independent predictor of prognosis. Urology 2010; 76: 12061209
  • 17
    Kollermann J, Helpap B. Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue. Am J Clin Pathol 2001; 116: 115121
  • 18
    Wikstrom P, Lissbrant IF, Stattin P, Egevad L, Bergh A. Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 2002; 51: 268275
  • 19
    McGarvey TW, Stearns ME. Keratinocyte growth factor and receptor mRNA expression in benign and malignant human prostate. Exp Mol Pathol 1995; 63: 5262
  • 20
    Hagglof C, Hammarsten P, Josefsson A et al. Stromal PDGFRbeta expression in prostate tumors and non-malignant prostate tissue predicts prostate cancer survival. PLoS ONE 2010; 5: e10747